Benign Prostatic Hyperplasia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Benign Prostatic Hyperplasia stocks.

Benign Prostatic Hyperplasia Stocks Recent News

Date Stock Title
Nov 21 LLY Eli Lilly, Verge announce milestones in ALS collaboration
Nov 21 LLY Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Nov 20 LLY Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’
Nov 20 LLY Eli Lilly in pact with Chinese biotech for novel weight loss therapy
Nov 20 LLY More companies covering weight loss drugs for their employees
Nov 20 LLY Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
Nov 20 BSX Boston Scientific Corporation (BSX)’s Breakthroughs: A Hidden Gem in Billionaire Ken Griffin’s Portfolio
Nov 20 LLY China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Nov 20 LLY Eli Lilly Option Trade Produces $1,125, If You Can Tolerate The Heavy Risk
Nov 20 LLY Is It Time to Sell Eli Lilly and Pfizer Stocks?
Nov 20 LLY Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
Nov 20 LLY The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley
Nov 20 LLY RFK Jr. Sparks New Worries About Obesity Drugs. Here’s What Investors Should Focus on Instead.
Nov 19 LLY Lilly announces changes on board of directors
Nov 19 LLY Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley
Nov 19 LLY LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study
Nov 19 LLY Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?
Nov 19 LLY Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%
Nov 19 LLY Jim Cramer: Coinbase Is A 'Winner,' Suggests Buying This 'Hated' Big Pharma Stock
Nov 19 LLY Here’s Why Eli Lilly and Company (LLY) is on Detractors’ List of Madison Sustainable Equity Fund
Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.The cause is unclear. Risk factors include a family history, obesity, type 2 diabetes, not enough exercise, and erectile dysfunction. Medications like pseudoephedrine, anticholinergics, and calcium channel blockers may worsen symptoms. The underlying mechanism involves the prostate pressing on the urethra thereby making it difficult to pass urine out of the bladder. Diagnosis is typically based on symptoms and examination after ruling out other possible causes.Treatment options including lifestyle changes, medications, a number of procedures, and surgery. In those with mild symptoms weight loss, exercise, and decreasing caffeine intake is recommended. In those with more significant symptoms medications may include alpha blockers such as terazosin or 5α-reductase inhibitors such as finasteride. Surgical removal of part of the prostate may be carried out in those who do not improve with other measures. Alternative medicine, such as saw palmetto, does not appear to help.About 105 million people are affected globally. BPH typically begins after the age of 40. Half of males age 50 and over are affected. After the age of 80 about 90% of males are affected. Although prostate specific antigen levels may be elevated in males with BPH, the condition does not increase the risk of prostate cancer.

Browse All Tags